In our latest #blog, Dr. Helen Baker, Director of Formulation Design, speaks on how our ASAPprime® software works at different stages of the development process and how customers can benefit from adding on analysis to their next drug program. quotientsciences.com/blog/obtaining…

#ICYMI: Martin Wing-King, VP and General Manager, Site Head, discusses the capabilities offered on-site at #Reading and expertise that our team offers in #formulationdevelopment for both simple and complex dosage forms. Read part two of our #blog feature: bit.ly/4e1T6UE

Attending the #PODD Conference next week? Our Chief Scientific Officer, Dr. Andy Lewis, will be there to discuss advances in oral #peptides and share more about our CDMO/CRO capabilities. Request a meeting with him at the event today: quotientsciences.com/events/podd-co…

#PressRelease The first clinical trial for a long-acting injectable for #malaria prevention by MMV and Quotient Sciences has begun. This innovative treatment could offer up to 3 months of protection with just one injection. Watch to learn more:

We're proud to partner with Medicines for Malaria Venture (MMV) to start the first clinical trial for a long-acting injectable form of MMV371. The trial, conducted in healthy volunteers in our Nottingham, UK clinic, marks a significant step toward preventing #malaria in endemic regions.

In an interview with Contract Pharma, Thierry Van Nieuwenhove, CEO at Quotient Sciences, discusses emerging trends in the #CDMO industry and the future of #drugdevelopment: quotientsciences.com/news/thierry-v…

Latest News: Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first #clinicaltrial at Quotient Sciences' Nottingham, UK facility for a long-acting injectable (LAI) preventive compound for malaria, MMV371. quotientsciences.com/news/quotient-…

Dr. Helen Baker, Director of Formulation Design, speaks on how ASAPprime® software works and customers can benefit from it to their next drug program: quotientsciences.com/blog/obtaining…

Our CEO, Thierry Van Nieuwenhove, spoke with @EPM_Magazine about how #QuotientSciences is innovating to meet the growing demand for more personalized medicine and tracking towards #sustainability goals: bit.ly/3Bu7N4B

We have been named a finalist in 2 categories of FierceBiotech's #FierceCROAwards. These celebrate exceptional achievements and innovations by CROs demonstrating outstanding performance, innovation, and leadership in delivering high-quality R&D services. quotientsciences.com/news/quotient-…

Latest News: Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first #clinicaltrial at Quotient Sciences' Nottingham, UK facility for a long-acting injectable (LAI) preventive compound for malaria, MMV371. quotientsciences.com/news/quotient-…

Dive into the life of a Principal Formulation Scientist at #QuotientSciences: Jordan Dickens shares more about his career and experience working with us in Nottingham, UK. bit.ly/4cbdGSb

We are proud to announce the installation of Centillion's™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product GMP platform technology for end to end RNA manufacture. Learn more: quotientsciences.com/news/quotient-…

In this article with Applied Clinical Trials, Martin Wing-King, VP and General Manager, discusses the complexity of bringing new treatments to market and how demand for accelerated pathways to first-in-human trials is growing across the pharmaceutical industry. quotientsciences.com/news/power-sim…

Dr. Andy Lewis, Chief Scientific Officer, and Dr. Stuart Mair, VP of Medical Consulting, reflect on latest developments in GLP-1s as a follow-up to our recent webinar series. Read more here: bit.ly/3TOlDoG

Hear from Alejandra Ugalde on what it's like working as a Screening Manager at our Miami, FL facility. Learn more about her #career and experience at #QuotientSciences: bit.ly/4bTvyQS

In this video interview with ManufacturingChemist, Dr. Andy Lewis, CSO, and Dr. Andrew Parker, Senior Drug Development Consultant, discussed the growing interest in oral #peptides and common challenges faced in #preclinical development at CPHI Milan. Watch here: bit.ly/3ZtWEu5

#SpeakPharma – Interview with Denise Sutton, COO and Site Head at Quotient Sciences’s Nottingham (UK) facility. Sutton discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. pharmacompass.com/speak-pharma/t…

In this #article with The Medicine Maker, Dr. Asma Patel, VP of Integrated Development Services, discusses how accelerating first-in-human #clinicaltrials is crucial in #drugdevelopment, especially for orphan drugs treating rare diseases. quotientsciences.com/news/dr-asma-p…